PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022 -





Summary

 
GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

 
GlobalData expects the MenACWY patient share to remain stagnant because of the market’s high level of maturity. In contrast, the MenB vaccine market appears poised to take off in the US. GlobalData anticipates that Pfizer will target adolescents with its MenB vaccine, an approach that should facilitate rapid uptake, given the ACIP’s current immunization recommendations (CDC, 2013b). On the other hand, the reluctance of policymakers to implement a routine infant program that does not offer serogroup B protection poses a challenge to companies that have targeted this age segment, such as GSK.

 
Scope

 
- Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

 
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.

 
- Sales forecast for the top drugs in the US from 2012-2022.

 
- Analysis of the impact of key events as well the drivers and restraints affecting the US Meningococcal Vaccines market.

 
Reasons to buy

 
- Understand and capitalize by identifying products that are most likely to ensure a robust return

 
- Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines

 
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

 
- Make more informed business decisions from insightful and in-depth analysis of drug performance

 
- Obtain sales forecast for drugs from 2012-2022 in the US
Drug And Medication Industry in the United States
Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Symptoms 15
3.3 Prognosis 16
4 Disease Management 17
4.1 Meningococcal Immunization Policy 18
4.2 US 20
4.2.1 Meningococcal Immunization Recommendations and Policies 20
4.2.2 Clinical Practice 22
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 25
5.3 Product Profiles – Major Brands 27
5.3.1 Menactra 27
5.3.2 Menveo 31
5.3.3 MenHibrix 34
5.3.4 Menomune 37
6 Opportunity and Unmet Need 41
6.1 Overview 41
6.2 Unmet Needs 42
6.2.1 Unmet Need: Protection Against Serogroup B Disease 42
6.2.2 Unmet Need: A Pentavalent (MenABCWY) Vaccine 43
6.2.3 Unmet Need: More Cost-Effective Vaccines 44
6.2.4 Unmet Need: Improved Duration of Immunity in Children and Adolescents 45
6.2.5 Unmet Need: Immunogenic Infant Vaccines 46
6.2.6 Unmet Need: Improved Vaccination Coverage Rates 47
6.2.7 Unmet Need: Increased Patient Awareness and Education 48
6.3 Unmet Needs Gap Analysis 49
6.4 Opportunities 49
6.4.1 Opportunity: Broadening Serogroup Protection with New and Existing Antigen Combinations 49
6.4.2 Opportunity: Improving Immune Response Duration with Adjuvants 50
6.4.3 Opportunity: Developing More Cost-Effective Vaccines by Partnering with Manufacturers in Emerging Markets 51
7 Pipeline Assessment 52
7.1 Overview 52
7.2 Promising Vaccines in Clinical Development 53
7.2.1 MnB rLP2086 55
7.3 Promising Vaccines in Early Clinical Development 60
8 Market Outlook 61
8.1 United States 61
8.1.1 Forecast 61
8.1.2 Key Events 65
8.1.3 Drivers and Barriers 66
9 Appendix 70
9.1 Bibliography 70
9.2 Abbreviations 80
9.3 Methodology 82
9.4 Forecasting Methodology 82
9.4.1 Vaccine Coverage 83
9.4.2 Vaccine Approval vs. Routine Schedule Inclusion 83
9.4.3 Vaccines Included 84
9.4.4 Key Launch Dates 85
9.4.5 General Pricing Assumptions 86
9.4.6 Individual Vaccine Assumptions 86
9.4.7 Pricing of Pipeline agents 88
9.5 Physicians and Specialists Included in this Study 89
9.6 About the Authors 92
9.6.1 Authors 92
9.6.2 Reviewers 92
9.6.3 Global Head of Healthcare 93
9.7 About GlobalData 94
9.8 Disclaimer 94



List of Tables

Table 1: Symptoms of Meningococcal Disease 16
Table 2: Meningococcal Immunization Recommendation Agencies by Country 18
Table 3: Recommended Routine Coverage and Most Administered Meningococcal Vaccines by Country in the Global Markets, 2012 19
Table 4: Leading Vaccines for Meningococcal Disease, 2012 26
Table 5: Product Profile – Menactra 28
Table 6: Menactra SWOT Analysis, 2012 30
Table 7: Product Profile – Menveo 32
Table 8: Menveo SWOT Analysis, 2012 34
Table 9: Product Profile – MenHibrix 35
Table 10: MenHibrix SWOT Analysis, 2012 37
Table 11: Product Profile – Menomune 38
Table 12: Menomune SWOT Analysis, 2012 40
Table 13: Overall Unmet Needs – Current Level of Attainment 41
Table 14: Clinical Unmet Needs – Gap Analysis, 2012 49
Table 15: Meningococcal Vaccines – Phase Pipeline, 2012 54
Table 16: Comparison of Vaccines in Development for Meningococcal Disease, 2012 55
Table 17: Product Profile – MnB rLP2086 56
Table 18: MnB rLP2086 SWOT Analysis, 2012 59
Table 19: Sales Forecasts ($m) for Meningococcal Vaccines in the United States, 2012–2022 63
Table 20: Key Events Impacting Sales for Meningococcal Vaccines in US, 2012 65
Table 21: United States Meningococcal Vaccines Market – Drivers and Barriers, 2012–2022 66
Table 22: Key Launch Dates 85
Table 23: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 91



List of Figures

Figure 1: Membrane Structure of N. meningitidis 13
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Meningococcal Vaccines, 2012–2022 54
Figure 3: Sales for Meningococcal Vaccines in the United States by Vaccine Class, 2012–2022 64